Connect your AI

Protagonist Therapeutics PTGX Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

Eli LillyLLY

26.3×-20.7×

AmgenAMGN

20.6×-6.3×

IncyteINCY

3.3×+0.1×

AbbVieABBV

261×+221×

Spyre Therapeutics, Inc.SYRE

5.9×+3.9×

Other financials

Income statement

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Calculated from Protagonist Therapeutics’s reported figures.

market cap/total stockholders equity=10.3×

Based on the most recent quarter.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Protagonist Therapeutics's price / book?: Protagonist Therapeutics (PTGX) reported price / book of 10.3× in Q1 2026.
How has Protagonist Therapeutics's price / book changed year-over-year?: Protagonist Therapeutics's price / book increased by 138.2% year-over-year, from 4.3× to 10.3×.
What is the long-term trend for Protagonist Therapeutics's price / book?: Over 5 years (2020 to 2025), Protagonist Therapeutics's price / book has grown at a 20.9% compound annual growth rate (CAGR), from 3.4× to 8.9×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.